Effect of hyperthermic chemotherapy on topical hemostatic agents
- 5 January 2022
- journal article
- research article
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 122 (3) , 164-168
Abstract
There is no clear consensus as to which topical hemostatic agent is best used during cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. The aim of this study was to evaluate the effect of hyperthermic chemotherapy on the biomechanical properties of organic topical hemostatic agents and histologically fibrin formation rates. Four topical hemostatic agents (Spongostan™, Surgicel®, Fibrillar™, Arista®) were evaluated. All agents were mixed with 3 ml blood in sterile tubes separately to form clot formation. The resulting clot formations were incubated with 36 °C and 42 °C with saline or cisplatin for 1 h. Strength and flexibility of hemostatic samples were evaluated under weight of 0 g, 50 g, 100 g, 200 g and 300 g. All samples were stained with hemotoxylin-eosin and compared histologically for fibrin clot formation under light microscope. There were no statistically significant differences according to strength and flexibility of topical hemostatic agents on hyperthermic chemotherapy. Histopathologically, the highest fibrin formation was observed in Surgicel®, followed by Fibrillar™. The least fibrin formation was detected in Arista®. This study demonstrated that exposure to hyperthermic chemotherapy did not significantly affect the biomechanical properties of organic topical hemostatic agents and the fibrin clot formation.Keywords
This publication has 16 references indexed in Scilit:
- Hemostatic efficacy and tissue reaction of oxidized regenerated cellulose hemostatsCellulose, 2013
- Topical hemostatic agents in surgical practiceTransfusion and Apheresis Science, 2011
- Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy—A Journey to Becoming a Nationally Funded Peritonectomy CenterAnnals of Surgical Oncology, 2007
- Perioperative hemostasis and thrombosisCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2006
- Comprehensive management of diffuse malignant peritoneal mesotheliomaEuropean Journal of Surgical Oncology, 2006
- Decision-making and technical factors account for the learning curve in complex surgeryJournal of Public Health, 2006
- Absorbable hemostatic agentsAmerican Journal of Health-System Pharmacy, 2006
- Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective StudyAnnals of Surgical Oncology, 2006
- Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2003
- The cellular and molecular basis of hyperthermiaCritical Reviews in Oncology/Hematology, 2002